Outcomes of the Paediatric ARV Drug Optimization 4 (PADO 4) and Paediatric Hepatitis C Drug Optimization meetings

Webinar

Organized by the Global Accelerator for Paediatric Formulations (GAP-f – www.gap-f.org)
19 December 2018, 14:00-15:00 CET – Join here

Overview

Over the past few years, global stakeholders have come together to enable more focused and coordinated action to make age-appropriate optimal formulations rapidly available to infants, children and adolescents living with HIV where they live. Several work streams have now been grouped under the umbrella of the Global Accelerator for Paediatric Formulations (GAP-f: www.gap-f.org). These include the WHO-led Paediatric ARV Drug Optimization (PADO) group which has established a set of mid and long-term priorities for drug development to accelerate access to optimal formulations in the context of fragmented markets for ARVs. The PADO has provided an evidence-based priority list with a clear and consistent message to guide industry and interested stakeholders on the most needed formulations to be developed. The list has helped reducing the number of unnecessary formulations being developed, and continues to be a critical tool to focus efforts and resources. The Paediatric ARV Drug Optimization 4 (PADO 4) and Paediatric Hepatitis C Drug Optimization meetings took place from 10-12 December 2018.

The Paediatric ARV Drug Optimization 4 (PADO 4) meeting took place in December 2018; its objectives were to:
• Review medium- and long-term priorities for the development of new ARV drugs and formulations for paediatric HIV treatment and prevention.
• Identify research gaps to be addressed and inform optimal use of ARVs in infants, children and adolescents to enable future development and uptake of priority products.
• Identify evidence gaps and key principles to guide investigation of ARVs in pregnant and lactating women.

The Paediatric Hepatitis C Drug Optimization meeting took place in December 2018; its objectives were to:
• Identify mid and longer-term priorities for development of paediatric formulations for HCV DAA to guide industry and relevant stakeholders
• Identify research gaps to inform approval, development and optimal use of HCV DAAs in children
• Identify key strategies to promote access to DAA treatment among children and adolescents.

The GAP-f invites you to a webinar to report on these two prioritization exercises. The webinar will cover paediatric HIV and HCV drug optimization and take place on Wednesday, 19 December 2018, 14:00-15:00 CET; join here.

Agenda

| 14:00 CET | Welcome and introduction |
| Sébastien Morin (IAS, Switzerland) |
| 14:05 CET | HIV – Paediatric ARV Drug Optimization 4 (PADO 4) |
| Martina Penazzato (WHO, Switzerland) |
| 14:30 CET | HCV – Paediatric Hepatitis C Drug Optimization |
| Philippa Easterbrook (WHO, Switzerland) |
| 14:45 CET | Q&A |
| Facilitated by Sébastien Morin (IAS, Switzerland) |
| 14:55 CET | Closing remarks |
| Sébastien Morin (IAS, Switzerland) |
How to join the virtual meeting

Please register prior to each webinar (see hyperlinks above). In case of any problem, please reach out to Guillaume Palfi, ICT Project Manager, Systems, guillaume.palfi@iasociety.org.

If joining by computer, please install the necessary Arkadin plug-in in advance.
- Mac computer  https://webexp.conferencing-tools.com/ArkadinSoftphoneInstallMac.aspx

If joining by smartphone or tablet, please install the necessary WebEx and Arkadin applications in advance.

Further details for the Arkadin plug-in installation are available below:

Windows computer

Mac computer

If the plugin installs successfully but does not work in WebEx (i.e. WebEx asks to install again), follow these steps:
1. On your MAC desktop, click on Finder icon
2. When opened, in the top menu, select “Go” and then “Go to Folder…”
3. Finally, type the following path: “~/Library/Application Support” and click on Go.